Drugmakers Glenmark Pharma, Cipla plan to step up US manufacturing

The US already contributes a significant share, around a quarter, of Cipla's total revenues

Drugmakers Cipla Limited and Glenmark Pharmaceuticals are open to expanding their manufacturing footprint in the US — a move that could help shield them from potential disruptions linked to evolving tariff regime.

 

The US accounts for around a quarter of total revenue for both Cipla and Glenmark.

 

Cipla is “actively scaling operations in the US”, a key global market for generics, particularly in respiratory and oncology segments, said a person familiar with the development. The company currently operates four manufacturing facilities in New York (3) and Massachusetts (1), focusing on inhalation products, oral therapy sachets, and the production of tablets